TTRX trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TTRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 25, 2026, Turn Therapeutics Inc. (TTRX) has a Wall Street consensus price target of N/A, based on estimates from 2 covering analysts. The company has a market capitalization of $306M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TTRX trades at a trailing P/E of -44.7x. Analysts expect EPS to grow -55.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $2.3B | $18.54 | $38.80 | +109.3% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $5.9B | $28.41 | $40.00 | +40.8% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.9B | $31.20 | $42.25 | +35.4% | Buy | 65.0x | 12 |
 KYMRKymera Therapeutics, Inc. | $9.1B | $110.76 | $138.20 | +24.8% | Buy | — | 27 |
 PRAXPraxis Precision Medicines, Inc. | $7.1B | $252.96 | $611.69 | +141.8% | Buy | — | 18 |
 RVMDRevolution Medicines, Inc. | $39.8B | $186.99 | $253.47 | +35.5% | Buy | — | 25 |
 VRTXVertex Pharmaceuticals Incorporated | $133.0B | $523.93 | $573.50 | +9.5% | Buy | 27.8x | 56 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.9B | $805.02 | $856.80 | +6.4% | Buy | 13.5x | 49 |
 ABBVAbbVie Inc. | $504.7B | $285.64 | $294.00 | +2.9% | Buy | 20.5x | 44 |
 INVAInnoviva, Inc. | $1.5B | $20.66 | $38.00 | +83.9% | Buy | 8.5x | 10 |
Quick answers to the most common questions about buying TTRX stock.
The consensus price target for TTRX is $N/A, close to the current price of $10.28 (N/A% implied move). Based on 2 analyst estimates, the stock appears fairly valued near current levels.
TTRX has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
TTRX's current price is $10.28 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for TTRX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
TTRX is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TTRX stock forecast based on 2 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
TTRX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TTRX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.